Abterra Biosciences
San Diego
About Abterra Biosciences
Abterra Biosciences provides technologies that use the latest in next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. Abterra Biosciences assembles an interdisciplinary team of data scientists and biologists to reimagine the development of antibody therapeutics. Alicanto, a novel antibody discovery platform developed by Abterra Biosciences, identifies target-specific antibodies in serum. It identifies high-affinity antibodies without the need for time-consuming and inefficient cell selection, fusions, or cloning.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.4M
- Last round: Grant (Feb 2021)
- Website: abterrabio.com
- Phone: (888) 416-9305
Industries & Categories
Biopharma, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/abterra-biosciences-86212 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.